ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Last update: 13 Jan, 6:58AM

175.17

-3.33 (-1.87%)

  • 1D -1.87%
  • 5D 2.10%
  • 1M -0.58%
  • 6M -3.72%
  • YTD -2.38%
  • 1Y 6.87%
  • 5Y 109.11%
Previous Close 178.50
Open 176.86
Volume 3,989,606
Avg. Volume (3M) 6,347,139
Market Cap 309,549,891,584
Price / Earnings (TTM) 61.03
Price / Earnings (Forward) 14.20
Price / Sales 5.44
Price / Book 49.89
52 Weeks Range
153.58 (-12%) — 207.32 (18%)
Earnings Date 31 Jan 2025
TTM Dividend Yield 3.54%
Profit Margin 9.22%
Operating Margin (TTM) 28.93%
Diluted EPS (TTM) 2.88
Quarterly Revenue Growth (YOY) 3.80%
Quarterly Earnings Growth (YOY) -12.20%
Total Debt/Equity (MRQ) 1,174.81%
Current Ratio (MRQ) 0.640
Operating Cash Flow (TTM) 16.51 B
Levered Free Cash Flow (TTM) 17.74 B
Return on Assets (TTM) 7.72%
Return on Equity (TTM) 56.41%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bearish Mixed
Drug Manufacturers - General (Global) Bearish Mixed
Stock AbbVie Inc. Bearish Bullish

AIStockmoo Score

1.0
Analyst Consensus 5.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages -2.5
Technical Oscillators -0.5
Average 1.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ABBV 310 B 3.54% 61.03 49.89
JNJ 362 B 3.27% 25.97 4.99
PFE 152 B 6.28% 35.67 1.65
BMY 121 B 4.02% - 7.06
GSK 70 B 4.54% 23.00 3.73
LLY 706 B 0.66% 84.63 50.52

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.10%
% Held by Institutions 73.47%
52 Weeks Range
153.58 (-12%) — 207.32 (18%)
Price Target Range
191.00 (9%) — 224.00 (27%)
High 224.00 (Morgan Stanley, 27.88%) Buy
Median 206.00 (17.60%)
Low 191.00 (B of A Securities, 9.04%) Hold
Average 208.27 (18.90%)
Total 9 Buy, 2 Hold
Avg. Price @ Call 178.73
Firm Date Target Price Call Price @ Call
Citigroup 28 Jan 2025 205.00 (17.03%) Buy 176.90
12 Nov 2024 215.00 (22.74%) Buy 171.09
Truist Securities 08 Jan 2025 211.00 (20.45%) Buy 178.50
Piper Sandler 17 Dec 2024 220.00 (25.59%) Buy 175.38
B of A Securities 10 Dec 2024 191.00 (9.04%) Hold 175.67
Leerink Partners 22 Nov 2024 206.00 (17.60%) Buy 176.95
Wolfe Research 15 Nov 2024 205.00 (17.03%) Buy 164.99
JP Morgan 13 Nov 2024 200.00 (14.17%) Buy 170.35
BMO Capital 12 Nov 2024 208.00 (18.74%) Buy 171.09
Morgan Stanley 12 Nov 2024 224.00 (27.88%) Buy 171.09
31 Oct 2024 231.00 (31.87%) Buy 203.87
Guggenheim 06 Nov 2024 221.00 (26.16%) Buy 201.20
UBS 31 Oct 2024 200.00 (14.17%) Hold 203.87
Show more

No data within this time range.

  • 3M
Date Type Details
24 Jan 2025 Announcement Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
23 Jan 2025 Announcement AbbVie Completes Acquisition of Nimble Therapeutics
23 Jan 2025 Announcement AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
13 Jan 2025 Announcement AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
13 Jan 2025 Announcement AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
13 Jan 2025 Announcement AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
09 Jan 2025 Announcement AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07 Jan 2025 Announcement CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
03 Jan 2025 Announcement AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
13 Dec 2024 Announcement AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
11 Dec 2024 Announcement AbbVie Completes Acquisition of Aliada Therapeutics
09 Dec 2024 Announcement AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
09 Dec 2024 Announcement Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
08 Dec 2024 Announcement AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
07 Dec 2024 Announcement Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
25 Nov 2024 Announcement AbbVie to Present at Citi's 2024 Global Healthcare Conference
18 Nov 2024 Announcement Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
18 Nov 2024 Announcement AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
14 Nov 2024 Announcement AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
11 Nov 2024 Announcement AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
07 Nov 2024 Announcement Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
31 Oct 2024 Announcement AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
30 Oct 2024 Announcement AbbVie Reports Third-Quarter 2024 Financial Results
29 Oct 2024 Announcement SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM
28 Oct 2024 Announcement AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
Show more
TTM Dividend Yield 3.54%
5Y Average Dividend Yield 3.81%
Payout Ratio 213.59%
Expected Next Dividend Payment May 2025
Ex Date Announcement Date Payment Date Details
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Cash
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Cash
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Cash
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Cash
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Cash
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Cash
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Cash
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Cash
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Cash
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Cash
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Cash
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Cash
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Cash
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Cash
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Cash
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Cash
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Cash
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Cash
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Cash
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Cash
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Cash
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Cash
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Cash
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Cash
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Cash
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Cash
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Cash
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Cash
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Cash
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Cash
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Cash
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Cash
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Cash
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Cash
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Cash
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Cash
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Cash
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Cash
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Cash
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Cash
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Cash
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Cash
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Cash
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Cash
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Cash
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Cash
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Cash
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Cash
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.64 1 0.94
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria